Opendata, web and dolomites

PanINSULA

PanINSULA - The next first commercially sustainable and therapeutically effective beta cell therapy for diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PanINSULA project word cloud

Explore the words cloud of the PanINSULA project. It provides you a very rough idea of what is the project "PanINSULA" about.

emerged    limited    sugar    care    unhealthy    pancryos    insulin    patented    commercially    donor    amputations    permanent    day    hpscs    pluripotent    unparalleled    paninsula    levels    blood    contrast    cope    ages    safety    self    manufacturability    steady    premature    inject    automation    mostly    producing    population    risk    death    lifethreatening    islets    people    damaged    diet    inactivity    replace    purity    natural    complications    disease    accounts    scalability    hyperglycemia    therapy    generating    10    nerve    t1d    obesity    blindness    cells    fluctuations    scalable    technologies    damage    overweight    clinically    immune    times    cure    lifetime    protection    heart    region    cell    islet    physical    lack    implanted    severe    difficulties    kidney    treatment    hurdles    stem    purification    time    shortage    chronic    regulate    beta       last    transplantation    diabetes    cadaveric    competing    positions    patients    intensive    serious    secretion    final    keeping    glucose    efficient    prevalence    careful   

Project "PanINSULA" data sheet

The following table provides information about the project.

Coordinator
PANCRYOS IVS 

Organization address
address: OLE MAALOES VEJ 3
city: KOBENHAVN N
postcode: 2200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.pancryos.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PANCRYOS IVS DK (KOBENHAVN N) coordinator 50˙000.00

Map

 Project objective

Prevalence of diabetes is increasing among all ages in the European Region, mostly due to increases in overweight and obesity, unhealthy diet and physical inactivity. Today there are about 60 M people with diabetes in the EU, of which Type 1 Diabetes (T1D) accounts for between 5% and 10%. T1D patients must cope with a lifetime of intensive self-care (testing their blood sugar levels several times a day to inject insulin when required) and the risk of premature death. Even with careful management T1D patients can still have difficulties keeping a steady blood glucose level and over time these lifethreatening fluctuations, especially the chronic high blood sugar levels (hyperglycemia), can cause serious complications including heart disease, blindness, kidney failure and amputations due to nerve damage. Currently there is no cure for T1D and no new significant development or permanent therapy for diabetes has emerged in the last 70 years. Islet transplantation while effective is not a scalable therapy and limited to only the most severe T1D patients due to the shortage of cadaveric donor islets. Recent advances in generating insulin producing beta cells from pluripotent stem cells (hPSCs), positions stem cell-based therapy as a promising treatment for a wider population of T1D patients. A stem cell based therapy would replace the damaged beta cells in the patients and allow for a natural production and secretion of insulin to regulate the blood glucose levels. To make stem cell therapy a clinically and commercially viable treatment in diabetes, the following technical hurdles need to be addressed: safety (lack of purity), cost-effective scalability, and lack of immune protection of the implanted cells. Pancryos patented technology, in contrast to other available competing technologies, enables both purification and automation ensuring unparalleled safety and cost-efficient scalability and manufacturability of the final cell product PanINSULA.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PANINSULA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PANINSULA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More